Literature DB >> 17404251

Cutting Edge: B cell receptor (BCR) cross-talk: the IL-4-induced alternate pathway for BCR signaling operates in parallel with the classical pathway, is sensitive to Rottlerin, and depends on Lyn.

Benchang Guo1, Derek Blair, Thomas C Chiles, Clifford A Lowell, Thomas L Rothstein.   

Abstract

B cell exposure to IL-4 alters subsequent BCR signaling such that ERK phosphorylation becomes signalosome-independent; however, the nature of this new, alternate signaling pathway and its relationship to the classical, signalosome-dependent signaling pathway are not known. In this study, we report that the alternate and classical pathways for BCR signaling are differentially affected by rottlerin, and by Go6976 or LY294002, respectively. Furthermore, in B cells lacking protein kinase C (PKC)beta, the classical pathway for BCR signaling is blocked, whereas the alternate pathway is little affected. Conversely, in B cells lacking Lyn, the alternate pathway for BCR signaling is blocked, whereas the classical pathway is little affected. The rottlerin-sensitive element is not PKCdelta, inasmuch as the alternate pathway is not blocked in PKCdelta-deficient B cells. These results indicate that the rottlerin-sensitive, Lyn-dependent alternate pathway, and the classical pathway, for BCR signaling operate in parallel when BCR engagement follows IL-4 exposure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404251     DOI: 10.4049/jimmunol.178.8.4726

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.

Authors:  T L Rothstein; B Guo
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

2.  Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses.

Authors:  Matthew L Wheeler; Matthew B Dong; Robert Brink; Xiao-Ping Zhong; Anthony L DeFranco
Journal:  Sci Signal       Date:  2013-10-15       Impact factor: 8.192

3.  B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways.

Authors:  Benchang Guo; Joseph R Tumang; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

4.  A novel Lyn-protein kinase Cδ/ε-protein kinase D axis is activated in B cells by signalosome-independent alternate pathway BCR signaling.

Authors:  Benchang Guo; Thomas L Rothstein
Journal:  Eur J Immunol       Date:  2013-04-12       Impact factor: 5.532

5.  Interpreting CFSE obtained division histories of B cells in vitro with Smith-Martin and cyton type models.

Authors:  Ha Youn Lee; Edwin Hawkins; Martin S Zand; Tim Mosmann; Hulin Wu; Philip D Hodgkin; Alan S Perelson
Journal:  Bull Math Biol       Date:  2009-04-21       Impact factor: 1.758

6.  The regulation of autoreactive B cells during innate immune responses.

Authors:  Barbara J Vilen; Jennifer A Rutan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  IL-4 upregulates Igα and Igβ protein, resulting in augmented IgM maturation and B cell receptor-triggered B cell activation.

Authors:  Benchang Guo; Thomas L Rothstein
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

8.  Protein kinase C signaling during T cell activation induces the endoplasmic reticulum stress response.

Authors:  Steven C Pino; Bryan O'Sullivan-Murphy; Erich A Lidstone; Thomas B Thornley; Agata Jurczyk; Fumihiko Urano; Dale L Greiner; John P Mordes; Aldo A Rossini; Rita Bortell
Journal:  Cell Stress Chaperones       Date:  2008-04-17       Impact factor: 3.667

9.  IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Authors:  Benchang Guo; Lu Zhang; Nicholas Chiorazzi; Thomas L Rothstein
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

10.  In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Authors:  Jason M Glover; Marc Loriaux; Jeffrey W Tyner; Brian J Druker; Bill H Chang
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.